Sonic Healthcare Ltd (ASX: SHL) experienced a notable rise in its share price as it emerged as one of the strongest performers on the S&P/ASX 200 Index (ASX: XJO) this past week. The company’s shares closed at $22.98 on Friday, marking an increase of 0.6%. Over the week, Sonic Healthcare shares surged by 7.8%, contrasting with a 2.5% decline in the benchmark Australian index. Despite this recent uptick, Sonic’s shares are down 16.6% over the past year, lagging behind the ASX 200’s modest gain of 1.1%.
Investors should also consider the dividends paid by Sonic Healthcare, which totalled $1.07 per share during this period. At the closing price on Friday, the stock offered a partly franked trailing dividend yield of 4.7%. This provides context for Sonic’s share price performance and investor returns.
Macquarie’s Target and Outlook for Sonic Healthcare
Following a robust week, market attention shifted towards what Macquarie Group Ltd (ASX: MQG) forecasts for Sonic Healthcare’s stock. Much of the recent strong performance can be attributed to Sonic’s annual general meeting (AGM) held on Thursday, where management provided an update on their trading outlook for the fiscal year 2026.
After the AGM, Sonic Healthcare shares saw a significant jump of 6.3%. The company reaffirmed its guidance for full-year earnings before interest, taxes, depreciation, and amortisation (EBITDA), projecting figures between $1.87 billion and $1.95 billion on a constant currency basis. If Sonic achieves the higher end of this range, it would represent a 12.7% increase in EBITDA compared to fiscal year 2025.
Macquarie’s analysis of Sonic’s FY 2026 guidance reflects the company’s expectation of a second-half weighting of EBITDA at approximately 54-55%, which aligns with historical seasonal patterns. However, Macquarie noted potential margin dilution due to Sonic’s recent acquisitions, including LADR and Swiss businesses, as well as a contract in the UK.
The broker also observed that Sonic anticipates potential changes to the US Protecting Access to Medicare Act (PAMA), with guidance excluding an estimated A$15 million impact from fee reductions expected in January 2026.
Despite these considerations, Macquarie has maintained a neutral rating on Sonic Healthcare shares. The firm has set a 12-month price target of $25.20 per share, indicating a potential upside of nearly 10% from Friday’s closing price. This target does not account for the two upcoming dividends, which could enhance shareholder returns.
Macquarie concluded its analysis by acknowledging the potential synergy benefits from Sonic’s recent acquisitions while also highlighting risks such as margin pressures and elevated leverage in the near term. They emphasized that uncertainties remain surrounding PAMA, Fair Work decisions, and the overall impact of fee cuts.
The insights provided by Macquarie offer a comprehensive outlook for investors considering Sonic Healthcare shares as part of their portfolio strategy.
